Elsevier Inc.

SHERPA: Unknown

People

  1. Arbour
    Arbour
  2. Plodkowski
    Plodkowski
  3. Preeshagul
    Preeshagul
  4. Riely
    Riely
  5. Rudin
    Rudin
  6. Boe
    Boe
  7. Eichholz
    Eichholz
  8. Ginsberg
    Ginsberg
  9. Girshman
    Girshman
  10. Gomez
    Gomez

Groups

  1. Department of Medicine (11)
  2. Solid Tumor Oncology Division (11)
  3. Thoracic Oncology (11)
  4. Body Imaging Service (5)
  5. Radiology, Department of (5)
  6. GSK Faculty (3)
  7. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2)
  8. Computational Oncology Service (2)
  9. Epidemiology and Biostatistics (2)
  10. Surgery (2)
Search Within
  1. "Thoracic Oncology"
  2. "Kathryn Arbour"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (3)
Groups
  1. Department of Medicine (11)
  2. Solid Tumor Oncology Division (11)
  3. Thoracic Oncology (11)
  4. Body Imaging Service (5)
  5. Radiology, Department of (5)
  6. GSK Faculty (3)

More Groups

People
  1. Kathryn Arbour (11)
  2. Matthew Hellmann (8)
  3. Hira Rizvi (7)
  4. Andrew Plodkowski (5)
  5. Isabel Preeshagul (3)
  6. Charles Rudin (2)

More People

Years
  1. 2023 (1)
  2. 2022 (2)
  3. 2021 (2)
  4. 2019 (3)
  5. 2018 (2)
  6. 2017 (1)
Publications
  1. Journal of Thoracic Oncology (8)
  2. European Journal of Cancer (1)
  3. Hematology/Oncology Clinics of North America (1)
  4. International Journal of Radiation Oncology, Biology, Physics (1)

Results (11)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The impact of co-alterations on outcomes after local therapy for patients with KRAS-mutant lung adenocarcinoma brain metastases
    Meeting Abstract

    Eichholz, J.; Gaeta, B.; Walch, H.; Boe, L.; Kratochvil, L.; del Balzo, L. A.; Yamada, Y.; Yu, Y.; Zinovoy, M.; Gomez, D. R.; more...
    International Journal of Radiation Oncology, Biology, Physics (2023)

    Fulltext@MSK | Save
  • Phase I A study to evaluate GDC-6036 monotherapy in patients with non-small cell lung cancer (NSCLC) with KRAS G12C mutation
    Meeting Abstract

    Sacher, A.; Patel, M. R.; Miller, W. H. Jr; Desai, J.; Garralda, E.; Bowyer, S.; Kim, T. W.; De Miguel, M.; Falcon, A.; Krebs, M. G.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma Is affected by KRAS mutation status
    Journal Article

    Ricciuti, B.; Arbour, K. C.; Lin, J. J.; Vajdi, A.; Vokes, N.; Hong, L.; Zhang, J.; Tolstorukov, M. Y.; Li, Y. Y.; Spurr, L. F.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
    Journal Article

    Mezquita, L.; Preeshagul, I.; Auclin, E.; Saravia, D.; Hendriks, L.; Rizvi, H.; Park, W.; Nadal, E.; Martin-Romano, P.; Ruffinelli, J. C.; more...
    European Journal of Cancer (2021)

    Fulltext@MSK | Save
  • Diminished efficacy of PD-(L)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is impacted by KRAS mutation status
    Meeting Abstract

    Ricciuti, B.; Arbour, K.; Lin, J.; Vajdi, A.; Tolstorukov, M.; Hong, L.; Zhang, J.; Vokes, N.; Li, Y.; Spurr, L.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • STK11/LKB1 genomic alterations are associated with inferior clinical outcomes with chemo-immunotherapy in non-squamous NSCLC
    Meeting Abstract

    Skoulidis, F.; Arbour, K.; Hellmann, M.; Patil, P.; Marmarelis, M.; Owen, D.; Awad, M.; Murray, J.; Levy, B.; Hellyer, J.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Early change of dNLR is correlated with outcomes in advanced NSCLC patients treated with immunotherapy
    Meeting Abstract

    Mezquita, L.; Preeshagul, I.; Auclin, E.; Saravia, D.; Hendriks, L.; Rizvi, H.; Planchard, D.; Park, W.; Nadal, E.; Ruffinelli, J. C.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Multifactorial model to predict response to PD-(L)1 blockade in patients with high PD-L1 metastatic non-small cell lung cancer
    Meeting Abstract

    Arbour, K.; Oprescu, M.; Hakim, J.; Rizvi, H.; Leiserson, M.; Ginsburg, M.; Plodkowski, A.; Sauter, J.; Preeshagul, I.; Gillett, S.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 status with outcomes for immune checkpoint inhibitors in advanced NSCLC patients
    Meeting Abstract

    Mezquita, L.; Park, W.; Arbour, K.; Auclin, E.; Hendriks, L.; Planchard, D.; Saravia, D.; Ponce Aix, S.; Nadal, E.; Audigier-Valette, C.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Concurrent mutations in STK11 and KEAP1 is associated with resistance to PD-(L)1 blockade in patients with NSCLC despite high TMB
    Meeting Abstract

    Arbour, K.; Shen, R.; Plodkowski, A.; Rizvi, H.; Ni, A.; Long, N.; Halpenny, D.; Sanchez-Vega, F.; Rudin, C.; Riely, G.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save